NEW YORK, NY / ACCESS Newswire / December 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Charming Medical Limited ("Charming Medical" or the "Company") (NASDAQ:MCTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Charming Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 11, 2025, the U.S. Securities and Exchange Commission issued an order to halt trading of Charming Medical securities "because of potential manipulation in the securities of [the Company] effectuated through recommendations made to investors by unknown persons via social media to purchase, hold, and/or sell the securities of [the Company] and to send screenshots documenting their transaction, which appear to be designed to artificially inflate the price and trading volume of the [Company’s] securities[.]" As a result, trading in Charming Medical’s securities was suspended starting on November 12, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
COMTEX_471555640/2457/2025-12-27T13:43:08